9788419284624_Sadhu. MW Cardiología 4ed

232

Manual Washington de especialidades clínicas. Cardiología

12. Hughes RK, Knott KD, Malcolmson J, et al. Apical hypertrophic cardiomyopathy: the variant less known. J Am Heart Assoc . 2020;9:e015294. 13. Cirino AL, Seidman CE, Ho CY. Genetic testing and counseling for hypertrophic cardiomyopathy. Cardiol Clin . 2019;37:35-43. 14. Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Cir culation . 2011;124:40-7. 15. Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2000;36:1344-54. 16. Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail. 2018;6:364-75. 17. Moreno JD, Bach RG, Damiano RJ, et al. Phenylephrine provocation to evaluate the cause of mi tral regurgitation in patients with obstructive hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2021;14(5):e012656. 18. Yu EH, Omran AS, Wigle ED, et al. Mitral regurgitation in hypertrophic obstructive cardiomyop athy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol . 2000;36:2219-25. 19. Grigg LE, Wigle ED, Williams WG, et al. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative de cision making. J Am Coll Cardiol . 1992;20:42-52. 20. Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379(7):655-68. 21. Rowin EJ, Maron MS, Chan RH, et al. Interaction of adverse disease related pathways in hypertro phic cardiomyopathy. Am J Cardiol. 2017;120:2256-64. 22. Burns C, Bagnall RD, Lam L, et al. Multiple gene variants in hypertrophic cardiomyopathy in the era of next-generation sequencing. Circ Cardiovasc Genet. 2017;10:e001666. 23. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy . J Cardiovasc Magn Reson. 2012;14:13. 24. Nistri S, Olivotto I, Maron MS, et al. β blockers for prevention of exercise-induced left ventricular out flow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012;110:715-19. 25. Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular dia stolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short-and long-term effects. Circulation . 1985;72:853-64. 26. Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:1251-8. 27. Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic ob structive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet . 2020;396:759-69. 28. Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertro phic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet . 2021;397:2467-75. 29. Batzner A, Pfeiffer B, Neugebauer A, et al. Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol . 2018;72:3087-94. 30. Zytnick D, Heard D, Ahmad F, et al. Exploring experiences of hypertrophic cardiomyopathy diagno sis, treatment, and impacts on quality of life among middle-aged and older adults: an interview study. Heart Lung . 2021;50:788-93. 31. Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol. 2015;65:1915-28. 32. Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardio myopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) . Circulation . 2018;138:1387-98. 33. American Heart Association. HCM risk calculator. Last accessed 08/20/21. https://professional .heart.org/en/guidelines-and-statements/hcm-risk-calculator 34. American Heart Association. Hypertrophic cardiomyopathy for professionals. Last accessed 08/20/21. https://professional.heart.org/en/education/hypertrophic-cardiomyopathy-for-professionals 35. American Heart Association. Hypertrophic cardiomyopathy (HCM). Last accessed 08/20/21. https://www.heart.org/en/health-topics/cardiomyopathy/what-is-cardiomyopathy-in-adults/ hypertrophic-cardiomyopathy 36. Hypertrophic Cardiomyopathy Association. Last accessed 08/20/21. https://4hcm.org/ SAMPLE